F Al-Mufti1,2, K Amuluru3, R Sahni4,2, K Bekelis5, R Karimi6, J Ogulnick2, J Cooper4, P Overby4, R Nuoman4, A Tiwari7, K Berekashvili7, N Dangayach8, J Liang8, G Gupta9, P Khandelwal9, J F Dominguez4, T Sursal4, H Kamal2, K Dakay2, B Taylor9, E Gulko4,2, M El-Ghanem10, S A Mayer4,2, C Gandhi4,2. 1. From the Departments of Neurosurgery (F.A.-M., R.S., J.C., P.O., R.N., J.F.D., T.S., E.G., S.A.M., C.G.) Fawaz.Al-Mufti@wmchealth.org. 2. Neurology (F.A.-M., R.S., J.O., H.K., K.D., E.G., S.A.M., C.G.), Westchester Medical Center at New York Medical College, Valhalla, New York. 3. Department of Radiology (K.A.), Goodman Campbell Brain and Spine, Indianapolis, Indiana. 4. From the Departments of Neurosurgery (F.A.-M., R.S., J.C., P.O., R.N., J.F.D., T.S., E.G., S.A.M., C.G.). 5. Department of Neurosurgery (K. Bekelis), Catholic Health Services and Good Samaritan Hospital, West Islip, New York. 6. Department of Neurosurgery (R.K.), Hackensack University Medical Center, Hackensack, New Jersey. 7. Department of Neurosurgery (A.T., K. Berekashvili), New York University, New York, New York. 8. Department of Neurosurgery (N.D., J.L.), Icahn School of Medicine at Mount Sinai, New York, New York. 9. Department of Neurological Surgery (G.G., P.K., B.T.), Rutgers University, New Brunswick, New Jersey. 10. Department of Neurology (M.E.-G.), University of Arizona-Tuscon, Tuscon, Arizona.
Abstract
BACKGROUND AND PURPOSE: Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is associated with hypercoagulability. We sought to evaluate the demographic and clinical characteristics of cerebral venous thrombosis among patients hospitalized for coronavirus disease 2019 (COVID-19) at 6 tertiary care centers in the New York City metropolitan area. MATERIALS AND METHODS: We conducted a retrospective multicenter cohort study of 13,500 consecutive patients with COVID-19 who were hospitalized between March 1 and May 30, 2020. RESULTS: Of 13,500 patients with COVID-19, twelve had imaging-proved cerebral venous thrombosis with an incidence of 8.8 per 10,000 during 3 months, which is considerably higher than the reported incidence of cerebral venous thrombosis in the general population of 5 per million annually. There was a male preponderance (8 men, 4 women) and an average age of 49 years (95% CI, 36-62 years; range, 17-95 years). Only 1 patient (8%) had a history of thromboembolic disease. Neurologic symptoms secondary to cerebral venous thrombosis occurred within 24 hours of the onset of the respiratory and constitutional symptoms in 58% of cases, and 75% had venous infarction, hemorrhage, or both on brain imaging. Management consisted of anticoagulation, endovascular thrombectomy, and surgical hematoma evacuation. The mortality rate was 25%. CONCLUSIONS: Early evidence suggests a higher-than-expected frequency of cerebral venous thrombosis among patients hospitalized for COVID-19. Cerebral venous thrombosis should be included in the differential diagnosis of neurologic syndromes associated with SARS-CoV-2 infection.
BACKGROUND AND PURPOSE: Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is associated with hypercoagulability. We sought to evaluate the demographic and clinical characteristics of cerebral venous thrombosis among patients hospitalized for coronavirus disease 2019 (COVID-19) at 6 tertiary care centers in the New York City metropolitan area. MATERIALS AND METHODS: We conducted a retrospective multicenter cohort study of 13,500 consecutive patients with COVID-19 who were hospitalized between March 1 and May 30, 2020. RESULTS: Of 13,500 patients with COVID-19, twelve had imaging-proved cerebral venous thrombosis with an incidence of 8.8 per 10,000 during 3 months, which is considerably higher than the reported incidence of cerebral venous thrombosis in the general population of 5 per million annually. There was a male preponderance (8 men, 4 women) and an average age of 49 years (95% CI, 36-62 years; range, 17-95 years). Only 1 patient (8%) had a history of thromboembolic disease. Neurologic symptoms secondary to cerebral venous thrombosis occurred within 24 hours of the onset of the respiratory and constitutional symptoms in 58% of cases, and 75% had venous infarction, hemorrhage, or both on brain imaging. Management consisted of anticoagulation, endovascular thrombectomy, and surgical hematoma evacuation. The mortality rate was 25%. CONCLUSIONS: Early evidence suggests a higher-than-expected frequency of cerebral venous thrombosis among patients hospitalized for COVID-19. Cerebral venous thrombosis should be included in the differential diagnosis of neurologic syndromes associated with SARS-CoV-2 infection.
Authors: Seon-Kyu Lee; Maxim Mokin; Steven W Hetts; Johanna T Fifi; Marie-Germaine Bousser; Justin F Fraser Journal: J Neurointerv Surg Date: 2018-06-05 Impact factor: 5.836
Authors: Mayte Sánchez van Kammen; Diana Aguiar de Sousa; Sven Poli; Charlotte Cordonnier; Mirjam R Heldner; Anita van de Munckhof; Katarzyna Krzywicka; Thijs van Haaps; Alfonso Ciccone; Saskia Middeldorp; Marcel M Levi; Johanna A Kremer Hovinga; Suzanne Silvis; Sini Hiltunen; Maryam Mansour; Antonio Arauz; Miguel A Barboza; Thalia S Field; Georgios Tsivgoulis; Simon Nagel; Erik Lindgren; Turgut Tatlisumak; Katarina Jood; Jukka Putaala; Jose M Ferro; Marcel Arnold; Jonathan M Coutinho; Aarti R Sharma; Ahmed Elkady; Alberto Negro; Albrecht Günther; Alexander Gutschalk; Silvia Schönenberger; Alina Buture; Sean Murphy; Ana Paiva Nunes; Andreas Tiede; Anemon Puthuppallil Philip; Annerose Mengel; Antonio Medina; Åslög Hellström Vogel; Audrey Tawa; Avinash Aujayeb; Barbara Casolla; Brian Buck; Carla Zanferrari; Carlos Garcia-Esperon; Caroline Vayne; Catherine Legault; Christian Pfrepper; Clement Tracol; Cristina Soriano; Daniel Guisado-Alonso; David Bougon; Domenico S Zimatore; Dominik Michalski; Dylan Blacquiere; Elias Johansson; Elisa Cuadrado-Godia; Emmanuel De Maistre; Emmanuel Carrera; Fabrice Vuillier; Fabrice Bonneville; Fabrizio Giammello; Felix J Bode; Julian Zimmerman; Florindo d'Onofrio; Francesco Grillo; Francois Cotton; François Caparros; Laurent Puy; Frank Maier; Giosue Gulli; Giovanni Frisullo; Gregory Polkinghorne; Guillaume Franchineau; Hakan Cangür; Hans Katzberg; Igor Sibon; Irem Baharoglu; Jaskiran Brar; Jean-François Payen; Jim Burrow; João Fernandes; Judith Schouten; Katharina Althaus; Katia Garambois; Laurent Derex; Lisa Humbertjean; Lucia Lebrato Hernandez; Lukas Kellermair; Mar Morin Martin; Marco Petruzzellis; Maria Cotelli; Marie-Cécile Dubois; Marta Carvalho; Matthias Wittstock; Miguel Miranda; Mona Skjelland; Monica Bandettini di Poggio; Moritz J Scholz; Nicolas Raposo; Robert Kahnis; Nyika Kruyt; Olivier Huet; Pankaj Sharma; Paolo Candelaresi; Peggy Reiner; Ricardo Vieira; Roberto Acampora; Rolf Kern; Ronen Leker; Shelagh Coutts; Simerpreet Bal; Shyam S Sharma; Sophie Susen; Thomas Cox; Thomas Geeraerts; Thomas Gattringer; Thorsten Bartsch; Timothy J Kleinig; Vanessa Dizonno; Yildiz Arslan Journal: JAMA Neurol Date: 2021-11-01 Impact factor: 29.907
Authors: A Hakim; C Kurmann; K Pospieszny; T R Meinel; M A Shahin; M R Heldner; R Umarova; S Jung; M Arnold; M El-Koussy Journal: AJNR Am J Neuroradiol Date: 2022-05-26 Impact factor: 4.966
Authors: Brit Long; Brandon M Carius; Summer Chavez; Stephen Y Liang; William J Brady; Alex Koyfman; Michael Gottlieb Journal: Am J Emerg Med Date: 2022-01-21 Impact factor: 4.093
Authors: Kiran T Thakur; Arina Tamborska; Greta K Wood; Emily McNeill; David Roh; Imo J Akpan; Eliza C Miller; Alyssa Bautista; Jan Claassen; Carla Y Kim; Alla Guekht; Carlos A Pardo; Olajide Williams; David García-Azorín; Kameshwar Prasad; Erich Schmutzhard; Benedict D Michael; Sherry H-Y Chou; Andrea S Winkler; Tom Solomon; Mitchell S Elkind Journal: J Neurol Sci Date: 2021-06-05 Impact factor: 3.181